Research programme: AAV-cDNA gene therapeutics - Sangamo Therapeutics

Drug Profile

Research programme: AAV-cDNA gene therapeutics - Sangamo Therapeutics

Alternative Names: AAV-cDNA gene therapy - Sangamo Therapeutics

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fabry's disease

Most Recent Events

  • 15 May 2017 Preclinical trials in Fabry's disease in USA (Infusion)
  • 15 May 2017 Sangamo Therapeutics intends to file an IND application for Fabry's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top